SUBCLINICAL MESOTHELIOMA
Clinical trials for SUBCLINICAL MESOTHELIOMA explained in plain language.
Never miss a new study
Get alerted when new SUBCLINICAL MESOTHELIOMA trials appear
Sign up with your email to follow new studies for SUBCLINICAL MESOTHELIOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare cancer: oral pill targets early mesothelioma in High-Risk patients
Disease control TerminatedThis study tests an oral medication (decitabine/cedazuridine) in people with BAP1 gene mutations who have early-stage mesothelioma that is not yet causing symptoms. The goal is to see if the drug can stop the cancer from growing or shrink it. About 9 participants will receive tre…
Matched conditions: SUBCLINICAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Promising mesothelioma drug trial pulled before it even started
Disease control TerminatedThis study was designed to test the drug alrizomadlin (APG-115) in people with BAP1 cancer syndrome who have early-stage mesothelioma that does not yet need standard treatment. The goal was to see if the drug could stabilize or improve the disease. However, the trial was withdraw…
Matched conditions: SUBCLINICAL MESOTHELIOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC